Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of LAG525 combinations with spartalizumab and/or carboplatin in advanced triple-negative breast cancer
MOH_2019-10-02_007425Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing LAG525 + spartalizumab, LAG525 + spartalizumab + carboplatin and LAG525 + carboplatin (3 arms). Started Aug 2018; status: completed.
02
Drugs
ieramilimabspartalizumabcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2019-10-02_007425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-02_007425.